AstraZeneca demonstrates high specificity for ciPTEC-OAT1

1 september 2018

Using a validation set of 62 drugs, we developed a model that integrates multi-parametric data and drug exposure information, resulting in a sensitivity of 75% and a specificity of 100%. The assay is compatible with the requirements for early drug discovery screening and mitigation of the risk for nephrotoxicity.

In collaboration with AstraZeneca, we developed a novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery.

The work was published in Archives of Toxicology doi: 10.1007/s00204-018-2284-y


Terug naar overzicht